dsm-firmenich to separate its animal nutrition and health business from rest of group

The company said it believes that the full potential of the ANH business could be best realized through a different ownership structure. “All potential separation options will be considered.”

It plans to separate out the ANH unit over the course of the next year. It said the move will minimize its exposure to vitamins earnings volatility​​.

As part of the vitamin transformation program announced in June last year​​ dsm-firmenich said it continues to make considerable progress on its cost reduction plan including plant closures, route-to-market simplification, and optimized service levels.

“The company remains confident in realizing a contribution of €100m in adjusted EBITDA in 2024 and the full benefit of €200m in 2025.”

It is likely though that the Bovaer and Veramaris businesses will be retained within the wider group.

‘A logical outcome’

“This carve-out is a substantial structural step for the company and its culture, but one logical outcome of the strategic asset review announced earlier in second quarter of 2023. It follows the merger of the high margin specialty business of Firmenich with the portfolio of DSM, which combines both specialties across the full life-sciences verticals and high-volume, low margin businesses such as ANH.

“Synergies from the DSM and Firmenich merger aimed to make the combined group one of the fastest growing ingredients companies in the coming three to four years.

“The lower margins from the ANH business certainly were a drag to group EV/EBITDA and other multiples comparing them to peers such as Symrise, Chr Hansen, Croda, Givaudan, Kerry, and Novozymes which seem to be the aspirational peer group for financial investors from here,” commented Stefan Schmidinger, chief economist, Kemiex.